Caldeira, DanielDavid, CláudioCosta, JoãoFerreira, Joaquim JPinto, Fausto J.2018-03-122018-03-1220172055-6837http://hdl.handle.net/10451/32287Published on behalf of the European Society of Cardiology. All rights reserved. ©The Author 2017The non-vitamin K antagonist oral anticoagulants (NOACs) were approved for non-valvular atrial fibrillation (AF) but this term may be misnomer. Thus, the term non-mechanical and rheumatic mitral valvular (non-MARM) AF was proposed to exclude patients with valvular heart disease (VHD) without contraindications for NOACs. We aimed to review the efficacy and safety of NOACs in patients with AF and VHD compared to Vitamin K Antagonists (VKA).engApixabanDabigatranEdoxabanRivaroxabanValveBioprosthesisjournal article10.1093/ehjcvp/pvx028